Cipla

On June 28, 2024, Orchid Pharma Limited, based in Chennai, India, and the only Indian pharmaceutical company to have developed a New Chemical Entity (NCE), announced the launch of its new drug, Cefepime-Enmetazobactam. This innovative treatment has received approval for complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). In a significant collaboration, Orchid Pharma has partnered with Cipla Limited to facilitate the widespread and rapid distribution of this groundbreaking antibiotic combination throughout India. 

In May 2024, Cipla Limited  and its wholly owned subsidiary Cipla USA Inc announced that it has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from the United States Food and Drug Administration (USFDA). 

In March 2024, Sanofi India Limited  and Sanofi Healthcare India Private Limited (together referred as “Sanofi India”) and Cipla Limited  announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category. 

In February 2024, Cipla partnered with CSIR-Central Drug Research Institute (CSIR-CDRI) to co-develop an innovative ophthalmic solution for fungal keratitis, pooling their expertise and resources to create a safe and effective treatment.

In February 2024, Cipla received approval from the Central Drugs Standard Control Organization (CDSCO) to market the novel antibiotic plazomicin in India.

In November 2023, Cipla Limited announced its partnership with Training and Educational Centre for Hearing Impaired (TEACH) for a program aimed to inspire and motivate hearing-impaired students, preparing them for the corporate world.

In August 2023, Cipla announced the launch of CiplaMed 2.0, an enhanced version of the industry-leading knowledge platform for the medical fraternity.

In June 2023, Cipla Limited announced that it has been ranked 1st in the Pharmaceuticals & Healthcare Sector and 5th in the Top 50 Most Sustainable Companies at the 3rd edition of BW India’s Most Sustainable Companies Awards 2022-23.

Cipla Limited on April 17, 2023, announced that it has been awarded the ESG Champion Award in the ‘Pharmaceutical & Healthcare sector' category by KPMG at their ESG Conclave and Awards, 2023, held in Mumbai.

Cipla launches diagnostic device for diabetes, infectious diseases, cardiac markers, thyroid function, and other conditions.

Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets.

In July 2022, Cipla Health signed agreement to acquire Endura Mass, a renowned nutritional supplement.

In June 2022, Cipla partnered with Drugs for Neglected Diseases initiative (DNDi) to announce the launch of a four-in-one antiretroviral treatment for children living with HIV in South Africa.

In December 2021, Cipla received an Emergency Use Authorization (EUA) to market Cipmolnu (Molnupiravir 200mg) as an oral antiviral medication in India for the treatment of adult COVID-19 patients with a SpO2 >93% and a high risk of disease progression, including hospitalisation or death.

In September 2021, Cipla Limited subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation, a not-for-profit organisation, to leverage digital technologies and build digital healthcare infrastructure, according to the company's regulatory filing to the exchanges.

In August 2021, Cipla and Kemwell Biopharma signed a joint venture agreement for the development, production and commercialisation of biosimilars.

In August 2021, the generic version of Novartis Pharmaceuticals Corporation's Durezol® received the final approval from Cipla (Difluprednate Ophthalmic Emulsion - 0.05%)

In May 2021, the company posted financial results for Q4 FY21 with net revenues of Rs. 4,606 crore (US$ 622.7 million) and net profit of Rs. 412 crore (US$ 55.7 million).

In May 2021, Cipla launched a real-time COVID-19 detection kit ‘ViraGen’ that is based on multiplex polymerase chain reaction (PCR) technology.

In May 2021, it entered a licensing agreement with Eli Lilly, an American pharmaceutical company, to gain access to COVID-19 drugs. Under the agreement, Cipla received royalty-free, non-exclusive licensing rights to manufacture and commercialise the drug ‘Baricitinib’ in India.

In March 2021, Cipla received the final approval for its abbreviated new drug application (ANDA) for Sumatriptan Nasal Spray, 20 mg, from the United States Food and Drug Administration. In US, the product recorded sales worth ~US$ 53.3 million in 2020.

In March 2021, the company announced that its subsidiary, Cipla Gulf FZ LCC, will partner with Alvotech for marketing and distribution of four biosimilar medicines in Australia and New Zealand.

In January 2021, it announced to procure solar energy from a 20-MWac (megawatt, alternating current) group captive project in Tuljapur, Maharashtra, that was commissioned in partnership with AMP Energy India.

Cipla signed a licensing agreement with Multi G, a Belgium-based firm, to distribute its COVID-19 rapid antibody test kits across Europe

Cipla announced its entry into the anti-fungal product category with Clocip, a skin infection solution.

Cipla launched Cipremi, an experimental anti-viral drug remdesivir, having Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection

Received approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90 mcg (base)/actuation

Acquired four key brands from Wanbury for up to Rs. 89 crore (US$ 12.73 million) in order to strengthen its women’s health segment

Acquired the brand name and trademark rights for Vysov & Vysov M (Vildagliptin+ Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market

Acquired a novel and patented anti-infective product, Elores, from Venus Remedies Limited

Cipla received approval for generic version of Gilead Sciences, Inc’s Letairis

Received approval for Q-TIB from World Health Organisation (WHO)

Sold its stake in Chase

Acquired minority stake in US-based Chase Pharma

Acquired 100% stake in Medpro South Africa

Set up formulation facility in Baddi, Himachal Pradesh

Set up four state-of-the-art manufacturing facilities in Goa

Strategic partnership with Ranbaxy

Launched several new products

Approval from FDA for bulk drug manufacturing plants

Name changed to Cipla

Set up of first research division

Incorporated in Mumbai, Maharashtra as Chemical Industrial & Pharmaceutical Laboratories Ltd